Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Byun, Hwa Kyung | - |
dc.contributor.author | Kim, Hyun Ju | - |
dc.contributor.author | Im, Yoo Ri | - |
dc.contributor.author | Kim, Do Young | - |
dc.contributor.author | Han, Kwang-Hyub | - |
dc.contributor.author | Seong, Jinsil | - |
dc.date.available | 2020-02-27T03:42:16Z | - |
dc.date.created | 2020-02-04 | - |
dc.date.issued | 2019-04 | - |
dc.identifier.issn | 0167-8140 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/1619 | - |
dc.description.abstract | Purpose: To evaluate the effects of dose escalation by intensity-modulated radiotherapy (IMRT) in liverdirected concurrent chemoradiotherapy for locally advanced Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma (BCLC-C HCC). Materials and methods: During 2005-2016, 637 patients with BCLC-C HCC received RT with concurrent hepatic arterial 5-fluorouracil. Patients were divided into two groups according to the biologically effective doses for a tumor (alpha/beta = 10 Gy): < 72 Gy (536 patients) and >= 72 Gy (101 patients). In each group, 128/536 (24%) and 94/101 patients (93%) used IMRT, respectively. Results: The median follow-up for patients alive at the time of analysis was 36 months (range, 6-159 months). For >= 72 Gy and < 72 Gy groups, the median overall survival (OS) was 21 and 13 months, respectively (P =.002). The 1-year local failure-free survival (LFFS) were significantly higher in high-dose group (95% vs. 79%; P <.001). After propensity score matching, high-dose group still had significantly better 1-year OS (62% vs. 51%; P =.03) and 1-year LFFS (95% vs. 78%; P =.008). In the multivariate model, RT dose was an independent predictor of LFFS and OS. The surgical conversion rate was significantly higher in high-dose group (20% vs. 12%, P =.03), with substantially increased median OS among patients who underwent surgery (104 months vs. 11 months; P <.001). There were no significant differences in gastrointestinal bleeding or radiation-induced liver disease. Conclusions: In liver-directed concurrent chemoradiotherapy, radiation dose escalation by IMRT increased LFFS and OS for locally advanced BCLC-C HCC. It also increased the conversion rate to curative resection, which was attributable to increased OS. (C) 2018 Elsevier B.V. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER IRELAND LTD | - |
dc.relation.isPartOf | RADIOTHERAPY AND ONCOLOGY | - |
dc.subject | CONFORMAL RADIATION-THERAPY | - |
dc.subject | VEIN TUMOR THROMBOSIS | - |
dc.subject | SURGICAL RESECTION | - |
dc.subject | CHEMOEMBOLIZATION | - |
dc.subject | SURVIVAL | - |
dc.subject | DISEASE | - |
dc.subject | BENEFIT | - |
dc.subject | TRIAL | - |
dc.title | Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000462762200001 | - |
dc.identifier.doi | 10.1016/j.radonc.2018.12.025 | - |
dc.identifier.bibliographicCitation | RADIOTHERAPY AND ONCOLOGY, v.133, pp.1 - 8 | - |
dc.identifier.scopusid | 2-s2.0-85059803264 | - |
dc.citation.endPage | 8 | - |
dc.citation.startPage | 1 | - |
dc.citation.title | RADIOTHERAPY AND ONCOLOGY | - |
dc.citation.volume | 133 | - |
dc.contributor.affiliatedAuthor | Kim, Hyun Ju | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Hepatocellular carcinoma | - |
dc.subject.keywordAuthor | Radiation dose-response relationship | - |
dc.subject.keywordAuthor | Intensity modulated radiotherapy | - |
dc.subject.keywordAuthor | Hepatic arterial infusion chemotherapy | - |
dc.subject.keywordPlus | CONFORMAL RADIATION-THERAPY | - |
dc.subject.keywordPlus | VEIN TUMOR THROMBOSIS | - |
dc.subject.keywordPlus | SURGICAL RESECTION | - |
dc.subject.keywordPlus | CHEMOEMBOLIZATION | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | BENEFIT | - |
dc.subject.keywordPlus | TRIAL | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.